person · Reporting owner

RAAB MICHAEL

Disclosed activity across 3 companies

Tapewire entity: 19876
SEC CIK: 0001321402

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARDELYX, INC.ARDX · Entity 4972	Director · President & CEO	August 21, 2026	August 25, 2026
Tempest Therapeutics, Inc.TPST · Entity 7734	Director	January 27, 2026	January 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARDELYX, INC.

Report date August 21, 2026 · Filed August 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,619,792	Ending reported balance After 2026-08-21 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-08-21 · Sale · Disposed 15,009 · Balance 1,663,357 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-08-21 · Sale · Disposed 15,976 · Balance 1,647,381 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-21 · Sale · Disposed 8,411 · Balance 1,638,970 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 4 · 2026-08-21 · Sale · Disposed 19,178 · Balance 1,619,792 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	24,364	Reported balance Holding disclosure · report date 2026-08-21 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 24,364 F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	1,000	Reported balance Holding disclosure · report date 2026-08-21 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,000 F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.

F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.

Tempest Therapeutics, Inc.

Report date January 27, 2026 · Filed January 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26	Direct	1,230	Reported balance After 2026-01-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMICUS THERAPEUTICS, INC.

Report date April 27, 2026 · Filed April 27, 2026

Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-27 transaction · row 1 1 source row Row 1 · 2026-04-27 · Disposition to issuer · Disposed 115,857 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09	Direct	Reported balance After 2026-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13	Direct	Reported balance After 2026-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27	Direct	Reported balance After 2026-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04	Direct	Reported balance After 2026-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10	Direct	Reported balance After 2026-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09	Direct	Reported balance After 2026-04-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08	Direct	Reported balance After 2026-04-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06	Direct	Reported balance After 2026-04-27 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05	Direct	Reported balance After 2026-04-27 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).

F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

F3: Each Option was fully vested.

F4: Each Option vested in full in connection with consummation of the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 02, 2025 Filed May 6, 2025 00:14 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	41,666	$4.25	$177,168.00	Disclosure SEC source: 0001628280-25-022355 · wk-form4_1746490444.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,594,754 F2 · price: Transaction was executed in multiple trades in prices ranging from $4.10 to $4.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
May 02, 2025 Filed May 6, 2025 00:14 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	20,833	$0.99	$20,624.67	Disclosure SEC source: 0001628280-25-022355 · wk-form4_1746490444.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,636,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. Read SEC document
April 04, 2025 Filed Apr 8, 2025 23:24 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	20,833	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-25-017125 · wk-form4_1744154658.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,667 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
April 04, 2025 Filed Apr 8, 2025 23:24 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	41,666	$4.59	$191,151.11	Disclosure SEC source: 0001628280-25-017125 · wk-form4_1744154658.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,615,587 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. F3 · price: Transaction was executed in multiple trades in prices ranging from $4.45 to $4.68, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
April 04, 2025 Filed Apr 8, 2025 23:24 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	20,833	$0.99	$20,624.67	Disclosure SEC source: 0001628280-25-017125 · wk-form4_1744154658.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,657,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,282 shares under the Ardelyx Employee Stock Purchase Plan in February 2025. Read SEC document
March 07, 2025 Filed Mar 8, 2025 00:25 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	20,834	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-25-011441 · wk-form4_1741393515.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,500 Underlying: Common Stock · 20,834 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
March 07, 2025 Filed Mar 8, 2025 00:25 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	41,668	$5.36	$223,198.81	Disclosure SEC source: 0001628280-25-011441 · wk-form4_1741393515.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,635,138 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.28 to $5.47, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
March 07, 2025 Filed Mar 8, 2025 00:25 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	20,834	$0.99	$20,625.66	Disclosure SEC source: 0001628280-25-011441 · wk-form4_1741393515.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,676,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. Read SEC document
February 25, 2025 Filed Feb 27, 2025 23:00 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	855,326	$0.00 Strike: $5.18	$0.00	Disclosure SEC source: 0001628280-25-008796 · wk-form4_1740697220.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 855,326 Underlying: Common Stock · 855,326 shares Expires 2035-02-25 F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 25, 2025, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
February 25, 2025 Filed Feb 27, 2025 23:00 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	570,217	$0.00	$0.00	Disclosure SEC source: 0001628280-25-008796 · wk-form4_1740697220.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,655,972 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
February 20, 2025 Filed Feb 21, 2025 23:54 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	22,964	$5.62	$129,124.28	Disclosure SEC source: 0001628280-25-007230 · wk-form4_1740182057.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,085,755 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.601611 to $5.625428, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
January 31, 2025 Filed Feb 1, 2025 01:16 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	20,833	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-25-003378 · wk-form4_1738372572.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,334 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 31, 2025 Filed Feb 1, 2025 01:16 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	41,666	$5.36	$223,354.76	Disclosure SEC source: 0001628280-25-003378 · wk-form4_1738372572.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,108,719 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.27 to $5.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
January 31, 2025 Filed Feb 1, 2025 01:16 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	20,833	$0.99	$20,624.67	Disclosure SEC source: 0001628280-25-003378 · wk-form4_1738372572.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,150,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. Read SEC document
January 07, 2025 Filed Jan 10, 2025 21:58 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	20,833	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-25-001178 · wk-form4_1736546315.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 499,167 Underlying: Common Stock · 20,833 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 07, 2025 Filed Jan 10, 2025 21:58 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	41,666	$5.31	$221,308.96	Disclosure SEC source: 0001628280-25-001178 · wk-form4_1736546315.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,129,552 F2 · price: Transaction was executed in multiple trades in prices ranging from $5.02 to $5.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
January 07, 2025 Filed Jan 10, 2025 21:58 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	20,833	$0.99	$20,624.67	Disclosure SEC source: 0001628280-25-001178 · wk-form4_1736546315.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,171,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024. Read SEC document
December 10, 2024 Filed Dec 13, 2024 00:02 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-24-051104 · wk-form4_1734048116.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 520,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
December 10, 2024 Filed Dec 13, 2024 00:02 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	25,000	$5.26	$131,620.00	Disclosure SEC source: 0001628280-24-051104 · wk-form4_1734048116.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,150,385 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.22 to $5.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
December 10, 2024 Filed Dec 13, 2024 00:02 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	25,000	$0.99	$24,750.00	Disclosure SEC source: 0001628280-24-051104 · wk-form4_1734048116.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,175,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
November 25, 2024 Filed Nov 28, 2024 01:15 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	25,000	$5.38	$134,482.50	Disclosure SEC source: 0001628280-24-049423 · wk-form4_1732756544.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,150,385 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.30 to $5.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
November 20, 2024 Filed Nov 22, 2024 23:31 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	31,980	$4.79	$153,328.11	Disclosure SEC source: 0001628280-24-049051 · wk-form4_1732318299.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,175,385 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
November 11, 2024 Filed Nov 12, 2024 22:00 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	2,743	$4.90	$13,440.70	Disclosure SEC source: 0001628280-24-047271 · wk-form4_1731448844.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,207,365 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
October 28, 2024 Filed Oct 31, 2024 12:24 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-24-044440 · wk-form4_1730377456.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 545,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
October 28, 2024 Filed Oct 31, 2024 12:24 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	25,000	$5.91	$147,740.00	Disclosure SEC source: 0001628280-24-044440 · wk-form4_1730377456.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,210,108 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.80 to $5.951, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
October 28, 2024 Filed Oct 31, 2024 12:24 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	25,000	$0.99	$24,750.00	Disclosure SEC source: 0001628280-24-044440 · wk-form4_1730377456.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,235,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
October 11, 2024 Filed Oct 15, 2024 21:01 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	7,500	$6.01	$45,075.00	Disclosure SEC source: 0001628280-24-042853 · wk-form4_1729026099.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,210,108 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
September 26, 2024 Filed Sep 27, 2024 20:09 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	3,000	$6.07	$18,210.00	Disclosure SEC source: 0001628280-24-041474 · wk-form4_1727467780.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,217,608 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
September 11, 2024 Filed Sep 13, 2024 20:35 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-24-040355 · wk-form4_1726259725.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 35,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
September 11, 2024 Filed Sep 13, 2024 20:35 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	35,000	$5.61	$196,399.00	Disclosure SEC source: 0001628280-24-040355 · wk-form4_1726259725.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,220,608 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F3 · price: Transaction was executed in multiple trades in prices ranging from $5.551 to $5.651, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,099 shares under the Ardelyx Employee Stock Purchase Plan in August 2024. Read SEC document
September 11, 2024 Filed Sep 13, 2024 20:35 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	35,000	$0.99	$34,650.00	Disclosure SEC source: 0001628280-24-040355 · wk-form4_1726259725.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,255,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,099 shares under the Ardelyx Employee Stock Purchase Plan in August 2024. Read SEC document
August 27, 2024 Filed Aug 28, 2024 21:45 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	7,500	$6.22	$46,635.00	Disclosure SEC source: 0001628280-24-038719 · wk-form4_1724881496.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,219,509 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: Transaction was executed in multiple trades in prices ranging from $6.161 to $6.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
August 20, 2024 Filed Aug 22, 2024 22:24 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	32,225	$5.86	$188,848.17	Disclosure SEC source: 0001628280-24-038289 · wk-form4_1724365438.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,227,009 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document
August 12, 2024 Filed Aug 14, 2024 22:16 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	1,229	$5.71	$7,017.59	Disclosure SEC source: 0001628280-24-037315 · wk-form4_1723673808.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,259,234 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
July 29, 2024 Filed Jul 31, 2024 23:54 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-24-033836 · wk-form4_1722470059.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 605,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
July 29, 2024 Filed Jul 31, 2024 23:54 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	30,000	$5.64	$169,314.00	Disclosure SEC source: 0001628280-24-033836 · wk-form4_1722470059.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,260,463 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.61 to $5.695, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
July 29, 2024 Filed Jul 31, 2024 23:54 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	30,000	$0.99	$29,700.00	Disclosure SEC source: 0001628280-24-033836 · wk-form4_1722470059.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,290,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:54 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	7,500	$5.97	$44,767.50	Disclosure SEC source: 0001628280-24-032114 · wk-form4_1721253256.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,260,463 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.92 to $6.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
June 28, 2024 Filed Jun 28, 2024 21:37 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	2,310	$6.59	$15,222.90	Disclosure SEC source: 0001628280-24-030513 · wk-form4_1719610633.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,267,963 F1 · kind: Transaction was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
June 13, 2024 Filed Jun 14, 2024 22:05 UTC	Tempest Therapeutics, Inc. TPST · Entity 7734	GrantStock Option (right to buy) · Derivative	16,000	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001415889-24-017009 · form4-06142024_060601.xml · derivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
June 13, 2024 Filed Jun 17, 2024 22:46 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001628280-24-028592 · wk-form4_1718664354.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 665,000 Underlying: Common Stock · 35,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
June 13, 2024 Filed Jun 17, 2024 22:46 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	35,000	$6.65	$232,743.00	Disclosure SEC source: 0001628280-24-028592 · wk-form4_1718664354.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,270,273 F1 · price: his transaction was executed in multiple trades in prices ranging from $6.601 to $6.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
June 13, 2024 Filed Jun 17, 2024 22:46 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionCommon Stock	35,000	$0.99	$34,650.00	Disclosure SEC source: 0001628280-24-028592 · wk-form4_1718664354.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,305,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 06, 2024 Filed Jun 7, 2024 23:44 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	42,467	$0.00 Strike: $10.27	$0.00	Disclosure SEC source: 0000950170-24-071003 · ownership.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,467 Underlying: Common Stock · 42,467 shares Expires 2034-06-06 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the one year anniversary of the date of grant. Read SEC document
June 06, 2024 Filed Jun 7, 2024 23:44 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	11,847	$0.00	$0.00	Disclosure SEC source: 0000950170-24-071003 · ownership.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,443 F1 · security: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in full on the one year anniversary of the grant date and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock. Read SEC document
May 29, 2024 Filed May 31, 2024 20:31 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	7,500	$6.72	$50,390.25	Disclosure SEC source: 0001628280-24-026063 · wk-form4_1717187463.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,270,273 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: Transaction was executed in multiple trades in prices ranging from $6.65 to $6.75, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
May 21, 2024 Filed May 23, 2024 20:13 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	31,484	$7.81	$245,921.52	Disclosure SEC source: 0001628280-24-024938 · wk-form4_1716495196.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,277,773 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,324 shares under the Ardelyx Employee Stock Purchase Plan in February 2024. Read SEC document
May 14, 2024 Filed May 15, 2024 22:15 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	3,000	$7.99	$23,970.00	Disclosure SEC source: 0001610717-24-000238 · form4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,307,933 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. Read SEC document
April 29, 2024 Filed May 1, 2024 23:59 UTC	ARDELYX, INC. ARDX · Entity 4972	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001610717-24-000228 · form4.xml · derivative · entry 5 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 670,000 Underlying: Common Stock · 30,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
April 29, 2024 Filed May 1, 2024 23:59 UTC	ARDELYX, INC. ARDX · Entity 4972	SaleCommon Stock	30,000	$6.40	$192,057.00	Disclosure SEC source: 0001610717-24-000228 · form4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,310,933 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 13, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $6.311 to $6.49, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.